MCID: BLD047
MIFTS: 39

Bladder Squamous Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Skin diseases

Aliases & Classifications for Bladder Squamous Cell Carcinoma

MalaCards integrated aliases for Bladder Squamous Cell Carcinoma:

Name: Bladder Squamous Cell Carcinoma 12 15 73
Epidermoid Carcinoma of the Urinary Bladder 12
Squamous Cell Carcinoma of Bladder 12
Carcinoma Squamous Cell Bladder 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3742
NCIt 50 C4031
UMLS 73 C0279681

Summaries for Bladder Squamous Cell Carcinoma

Disease Ontology : 12 A carcinoma of bladder that is manifested in squamous cells of the bladder.

MalaCards based summary : Bladder Squamous Cell Carcinoma, also known as epidermoid carcinoma of the urinary bladder, is related to squamous cell carcinoma and transitional cell carcinoma, and has symptoms including dysuria An important gene associated with Bladder Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Regulation of TP53 Activity and Endometrial cancer. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung.

Related Diseases for Bladder Squamous Cell Carcinoma

Diseases related to Bladder Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 30.6 CDKN2A S100A7 TP53
2 transitional cell carcinoma 29.9 CDKN2A TP53 UPK2
3 ductal carcinoma in situ 10.1 S100A7 TP53
4 keratinizing squamous cell carcinoma 10.1 CDKN2A TP53
5 spitz nevus 10.1 CDKN2A TP53
6 schistosomiasis 10.1
7 vulva squamous cell carcinoma 10.1 CDKN2A TP53
8 scrotal carcinoma 10.1 CDKN2A TP53
9 vulvar disease 10.1 CDKN2A TP53
10 nasal cavity adenocarcinoma 10.1 CDKN2A TP53
11 bartholin's gland disease 10.1 CDKN2A TP53
12 anal squamous cell carcinoma 10.1 CDKN2A TP53
13 megaesophagus 10.1 CDKN2A TP53
14 glycogen-rich clear cell breast carcinoma 10.1 CDKN2A TP53
15 gastric adenosquamous carcinoma 10.1 CDKN2A TP53
16 anogenital venereal wart 10.0 CDKN2A TP53
17 cervix uteri carcinoma in situ 10.0 CDKN2A TP53
18 uterus carcinoma in situ 10.0 CDKN2A TP53
19 oral leukoplakia 10.0 CDKN2A TP53
20 meningeal melanomatosis 10.0 CDKN2A TP53
21 suppressor of tumorigenicity 3 10.0 CDKN2A TP53
22 dedifferentiated liposarcoma 10.0 CDKN2A TP53
23 liposarcoma 10.0 CDKN2A TP53
24 endocervical adenocarcinoma 10.0 CDKN2A TP53
25 cervical adenocarcinoma 10.0 CDKN2A TP53
26 penile disease 10.0 CDKN2A TP53
27 cervix small cell carcinoma 10.0 CDKN2A TP53
28 small cell carcinoma 10.0 CDKN2A TP53
29 necrotizing sialometaplasia 10.0 CDKN2A TP53
30 verrucous carcinoma 10.0 CDKN2A TP53
31 basaloid squamous cell carcinoma 10.0 CDKN2A TP53
32 tongue disease 10.0 CDKN2A TP53
33 biliary tract neoplasm 10.0 CDKN2A TP53
34 optic nerve neoplasm 10.0 CDKN2A TP53
35 juvenile pilocytic astrocytoma 10.0 CDKN2A TP53
36 tonsil cancer 10.0 CDKN2A TP53
37 recessive dystrophic epidermolysis bullosa 10.0 CDKN2A TP53
38 vulva cancer 10.0 CDKN2A TP53
39 squamous cell papilloma 10.0 CDKN2A TP53
40 laryngeal disease 10.0 CDKN2A TP53
41 barrett's adenocarcinoma 10.0 CDKN2A TP53
42 oropharynx cancer 10.0 CDKN2A TP53
43 pharynx cancer 10.0 CDKN2A TP53
44 cervix carcinoma 10.0 CDKN2A TP53
45 pancreatic ductal carcinoma 10.0 CDKN2A TP53
46 skin squamous cell carcinoma 10.0 CDKN2A TP53
47 inverted papilloma 10.0 CDKN2A TP53
48 cellular schwannoma 10.0 CDKN2A TP53
49 penile cancer 10.0 CDKN2A TP53
50 in situ carcinoma 10.0 CDKN2A TP53

Graphical network of the top 20 diseases related to Bladder Squamous Cell Carcinoma:



Diseases related to Bladder Squamous Cell Carcinoma

Symptoms & Phenotypes for Bladder Squamous Cell Carcinoma

UMLS symptoms related to Bladder Squamous Cell Carcinoma:


dysuria

Drugs & Therapeutics for Bladder Squamous Cell Carcinoma

Drugs for Bladder Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 Interferon-alpha Phase 3
5 Antiviral Agents Phase 3,Phase 2
6 Adjuvants, Immunologic Phase 3
7 Anti-Bacterial Agents Phase 3
8 Pharmaceutical Solutions Phase 3
9 Immunologic Factors Phase 3,Phase 2,Phase 1
10 Antibiotics, Antitubercular Phase 3
11 Alkylating Agents Phase 3,Phase 2
12 Vaccines Phase 3,Phase 1
13 interferons Phase 3
14 Mitomycins Phase 3
15 Anti-Infective Agents Phase 3,Phase 2,Phase 1
16 Nucleic Acid Synthesis Inhibitors Phase 3
17 Topoisomerase Inhibitors Phase 3,Phase 2
18 Antimetabolites Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20 Antimetabolites, Antineoplastic Phase 3,Phase 2
21
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
22
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Gemcitabine Approved Phase 2 95058-81-4 60750
25
leucovorin Approved Phase 2 58-05-9 6006 143
26
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
27
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
28
Ifosfamide Approved Phase 2 3778-73-2 3690
29
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
32
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
33 Piritrexim Investigational Phase 2 72732-56-0
34
Rubitecan Investigational Phase 2 91421-42-0
35
Camptothecin Experimental Phase 2 7689-03-4
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Antineoplastic Agents, Phytogenic Phase 2
38 Antimitotic Agents Phase 2
39 Albumin-Bound Paclitaxel Phase 2
40 Vitamin B Complex Phase 2
41 Vitamin B9 Phase 2
42 Folic Acid Antagonists Phase 2
43 Folate Phase 2
44 topoisomerase I inhibitors Phase 2
45 Antineoplastic Agents, Alkylating Phase 2
46
Isophosphamide mustard Phase 2 0
47 Antibodies Phase 2,Phase 1
48 Immunoglobulins Phase 2,Phase 1
49 Antibodies, Monoclonal Phase 2,Phase 1
50 Micronutrients Phase 2

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
5 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
6 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
7 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
8 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
9 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
10 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
11 Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2 gemcitabine hydrochloride;cisplatin
12 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
13 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
14 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
15 Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment Completed NCT00016237 Phase 1
16 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
17 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1
18 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
19 Adjuvant Radiation for High Risk Bladder Cancer Recruiting NCT01954173 Not Applicable

Search NIH Clinical Center for Bladder Squamous Cell Carcinoma

Genetic Tests for Bladder Squamous Cell Carcinoma

Anatomical Context for Bladder Squamous Cell Carcinoma

MalaCards organs/tissues related to Bladder Squamous Cell Carcinoma:

41
Skin, Lymph Node, Lung, Bone, Tongue, Cervix, T Cells

Publications for Bladder Squamous Cell Carcinoma

Articles related to Bladder Squamous Cell Carcinoma:

(show all 16)
# Title Authors Year
1
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. ( 29980330 )
2018
2
Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma. ( 30460893 )
2018
3
Risk factors for development of primary bladder squamous cell carcinoma. ( 27869492 )
2016
4
Bladder squamous cell carcinoma in pregnancy. ( 26467844 )
2015
5
Vesicoenteric fistula due to bladder squamous cell carcinoma. ( 25045451 )
2014
6
Radiation treatment of bladder squamous cell carcinoma in a patient with spina bifida: A case report. ( 22709884 )
2012
7
Urinary schistosomiasis with simultaneous bladder squamous cell carcinoma and transitional cell carcinoma. ( 23109968 )
2012
8
p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. ( 22684221 )
2012
9
Enterovesical fistula caused by a bladder squamous cell carcinoma. ( 19725163 )
2009
10
Bladder squamous cell carcinoma. ( 15143234 )
2004
11
Bladder squamous cell carcinoma biomarkers derived from proteomics. ( 10892722 )
2000
12
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. ( 9515818 )
1998
13
Enhanced tumorigenicity of rat bladder squamous cell carcinoma cells after abrogation of gap junctional intercellular communication. ( 9685850 )
1998
14
Bladder squamous cell carcinoma with human papilloma virus type 6 [HPV 6]. ( 8749958 )
1995
15
UNME/K1: an IgG2a monoclonal antibody specific to cytokeratin of human urinary bladder squamous cell carcinoma. ( 1712997 )
1991
16
Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( 71361 )
1977

Variations for Bladder Squamous Cell Carcinoma

Expression for Bladder Squamous Cell Carcinoma

Search GEO for disease gene expression data for Bladder Squamous Cell Carcinoma.

Pathways for Bladder Squamous Cell Carcinoma

Pathways related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 CDKN2A CREBBP TP53
2
Show member pathways
12.51 CDKN2A CREBBP TP53
3 12.48 CDKN2A CREBBP TP53
4 12.11 CDKN2A CREBBP TP53
5 12.02 CDKN2A CREBBP TP53
6 11.86 CDKN2A CREBBP TP53
7 11.74 CDKN2A CREBBP TP53
8 11.65 CDKN2A TP53
9
Show member pathways
11.64 CREBBP TP53
10 11.52 CREBBP TP53
11 11.51 CREBBP TP53
12 11.44 CDKN2A TP53
13 11.43 CDKN2A TP53
14
Show member pathways
11.42 CDKN2A TP53
15 11.41 CDKN2A CREBBP TP53
16 11.37 CREBBP TP53
17 11.31 CREBBP TP53
18
Show member pathways
11.26 CREBBP TP53
19 11.22 CDKN2A TP53
20 11.09 CREBBP TP53
21 10.98 CDKN2A TP53
22 10.86 CDKN2A CREBBP TP53
23 10.75 CDKN2A TP53
24
Show member pathways
10.71 CDKN2A TP53
25 10.53 CDKN2A CREBBP TP53

GO Terms for Bladder Squamous Cell Carcinoma

Biological processes related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.5 CDKN2A CREBBP TP53
2 Ras protein signal transduction GO:0007265 9.26 CDKN2A TP53
3 cellular response to UV GO:0034644 9.16 CREBBP TP53
4 protein destabilization GO:0031648 8.96 CDKN2A CREBBP
5 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 p53 binding GO:0002039 9.26 CREBBP TP53
2 RNA polymerase II transcription factor binding GO:0001085 9.16 CREBBP TP53
3 transcription factor binding GO:0008134 9.13 CDKN2A CREBBP TP53
4 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Bladder Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....